GMAB
Genmab AS
38.50$
+10.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.2% | 35.7% | 36.3% | 28.1% | 36.7% | 5.1% | 272.7% | 6.7% | 52.4% | 28.5% | 0.3% | 4.4% | 21.6% | |
| 1.8% | 1.2% | 2.2% | 1.8% | 2.0% | 0.2% | 15.2% | 1.7% | 1.8% | 2.0% | 3.2% | 2.3% | 2.3% | |
| 3.4% | 3.3% | 4.0% | 3.5% | 3.4% | 0.3% | 23.8% | 3.6% | 3.3% | 3.4% | 5.4% | 3.2% | 3.8% | |
| 0.5% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -11.9% | 1.7% | 10.1% | -12.8% | -9.5% | 0.2% | 71.3% | -11.4% | 0.2% | 24.0% | -12.6% | -23.1% | -3.0% | |
| 2.1% | 1.4% | 0.7% | 0.5% | 0.9% | 0.4% | 28.5% | 1.1% | 0.2% | 1.2% | 0.6% | 0.3% | 0.6% | |
| 21.4% | -9.4% | -34.8% | -163.0% | 4.0% | 1.8% | -40.9% | 2.8% | -5.3% | -528.7% | -1.0% | 0.2% | -136.5% | |
| 0.8% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.1% | -0.1% | -13.1% | -56.2% | -5.3% | 0.6% | -78.7% | -43.9% | -2.3% | 0.0% | -10.7% | 0.0% | -2.9% | |
| -0.3% | – | – | – | 0.0% | 0.0% | -1.9% | -0.4% | -0.5% | -0.2% | -7.7% | -5.6% | -3.4% | |
| 0.4% | -0.5% | -14.1% | -56.5% | -5.0% | 0.6% | -12.4% | -43.9% | -2.1% | 496.2% | -19.8% | -6.5% | 120.1% | |
| 72.1% | 12.7% | -12.8% | -193.2% | 36.3% | 6.6% | 227.1% | -34.9% | 45.5% | -4.4% | -21.6% | -1.6% | 5.0% | |
| 41.2% | 34.3% | 35.7% | 27.6% | 35.8% | 4.6% | 244.2% | 5.6% | 52.3% | 27.2% | -0.2% | 4.2% | 21.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.